| Cash Flow | 2026-03-31 |
|---|---|
| Net loss | -38,262 |
| Depreciation and amortization | 1,171 |
| Loss (gain) from disposal of property and equipment | 33 |
| Right-of-use asset impairment expense | 0 |
| Accretion of discount on marketable securities | 296 |
| Stock-based compensation expense | 2,587 |
| Non-cash rent expense | 879 |
| Change in fair value of contingent consideration and warrant liability | 109 |
| Prepaid expenses and other current assets | -3 |
| Other non-current assets | 1,686 |
| Accounts payable | 484 |
| Lease liabilities | -1,225 |
| Accrued expenses and other current liabilities | -4,766 |
| Net cash used in operating activities | -41,035 |
| Maturities of marketable securities | 34,950 |
| Purchases of property and equipment | 148 |
| Proceeds from sale of property and equipment | 0 |
| Net cash provided by investing activities | 34,802 |
| Proceeds from stock options exercised | 651 |
| Payment of deferred offering costs | 143 |
| Principal payments on finance leases | 24 |
| Net cash provided by financing activities | 484 |
| Effect of exchange rate changes on cash, cash equivalents, and restricted cash | 24 |
| Decrease in cash, cash equivalents and restricted cash | -5,725 |
| Cash, cash equivalents and restricted cash, beginning of period | 44,897 |
| Cash, cash equivalents and restricted cash, end of period | 39,172 |
Odyssey Therapeutics, Inc. (ODTX)
Odyssey Therapeutics, Inc. (ODTX)